Recent news on Neorecormon

Roche executive says Mircera on track to be launched soon globally  -  25 May 2007
MarketWatchThe current market leader is Roche's NeoRecormon, and given that Mircera is easier to use its sales could surpass those of the older treatment, Kemmler said

US anaemia drug curbs weigh on Roche-analysts  -  May 11, 2007
ReutersAndrew Fellows, analyst at brokerage Helvea, noted NeoRecormon sales were likely slowing regardless and are mainly in dialysis indications, and so the FDA

Roche's Anaemia Therapies to Feature Strongly at Upcoming World ...  -  Apr 16, 2007
campus med,Eight posters feature results from trials with Roche's first anaemia drug, NeoRecormon. Highlights include further results from the GAIN trial,

Roche's Anaemia Therapies to Feature Strongly at Upcoming World ...  -  Apr 15, 2007
Juraforum.de,Eight posters feature results from trials with Roche's firstanaemia drug, NeoRecormon. Highlights include further results fromthe GAIN trial,

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),Sales of NeoRecormon grew by 3% despite a highly competitive environment. Sales of Epogin in Japan declined by 17% due to the impact of government-mandated

Shire undercuts rivals with launch of Dynepo drug  -  Mar 15, 2007
Reuters.uk,VX: Quote, Profile , Research) NeoRecormon. Dynepo was approved for treating anaemia in patients with chronic kidney disease in Europe in 2002 but its

Studies Show Anemia Drugs May Harm Cancer Patients  -  Feb 27, 2007
New York Times,Roche’s drugs NeoRecormon and Epogin, now sold only outside the United States, had sales last year of $1.8 billion. But Roche is hoping to enter the

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Anemia - NeoRecormon sales up for both indications Despite sustained pricing pressure, sales of NeoRecormon (epoetin beta) rose 6% to 1.5 billion Swiss

Sales at Roche growing three times faster than market  -  Feb 7, 2007
Pharma Times (subscription),A little more disappointing was the performance of the anaemia drugs NeoRecormon and Epogin (epoetin beta), combined sales of which slipped 1% to 2.23

NeoRecormon Gains European Approval For Convenient Once Weekly ...  -  18 Jan 2007
Medical News Today (press release),Roche announced today that it has received European marketing approval for a simple and convenient once weekly subcutaneous injection of NeoRecormon

Roche gets EU approval for once-weekly NeoRecormon  -  Jan 11, 2007
Pharma Times (subscription),Swiss drug major Roche says that its anaemia drug NeoRecormon has been granted European marketing approval to be used as a once-weekly treatment of the

Neorecormon Gains European Approval for Convenient Once Weekly ...  -  Jan 10, 2007
DG NewsNeoRecormon 30000 IU once weekly is proven to effectively (2) and rapidly (3,4), correct anaemia irrespective of the type of chemotherapy patients receive.

EU approves Roche's NeoRecormon for weekly dose  -  Jan 10, 2007
ReutersVX: Quote, Profile, Research) said on Wednesday the European Union had approved its NeoRecormon for once-weekly injection to treat cancer patients suffering

Roche's Neorecormon approved in EU for once-weekly anemia ...  -  Jan 9, 2007
Forbes,BASEL (AFX) - Swiss drug maker Roche Holding AG said its Neorecormon drug has been granted European approval for treatment of anaemia in patients with solid

Swiss shares fall in morning trade tracking Asia, DJIA  -  Jan 10, 2007
Forbes,The share was unaffected by news that its Neorecormon drug has been approved in the EU for once-weekly anemia treatment in patients with solid cancer.

European Markets Poised For Lower Open On Oil Prices, Fragile ...  -  Jan 10, 2007
Trading Markets,The shares of Swiss drug maker Roche Holding will remain in focus today after the company's Neorecormon drug was granted European approval for treatment of

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional